Immunization of guinea pigs with novel hepatitis b antigen as nanoparticle aggregate powders administered by the pulmonary route

AAPS Journal

Volumn 12, Issue 3, 2010, Pages 330-337

  Muttil, Pavan ^a,e   Prego, Cecilia ^b   Garcia Contreras, Lucila ^a   Pulliam, Brian ^b,c   Fallon, John Kevin ^a   Wang, Chenchen ^a   Hickey, Anthony James ^a,c   Edwards, David ^b,c,d  

^a University of North Carolina   (United States)

^b HARVARD UNIVERSITY   (United States)

^c Medicine in Need   (United States)

^d HARVARD UNIVERSITY   (United States)

^e UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

antibody titer; dry powder formulation; hepatitis B vaccine; pulmonary delivery

Indexed keywords

ALUMINUM POTASSIUM SULFATE; HEPATITIS B VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LEUCINE; MACROGOL; NANOPARTICLE; POLYGLACTIN; RECOMBINANT ANTIGEN; RECOMBINANT HEPATITIS B SURFACE ANTIGEN; SILVER NITRATE; UNCLASSIFIED DRUG; HEPATITIS B ANTIBODY; HEPATITIS B ANTIGEN;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRY POWDER; ENZYME LINKED IMMUNOSORBENT ASSAY; GUINEA PIG; LUNG LAVAGE; MALE; MUCOSAL IMMUNITY; NANOENCAPSULATION; NONHUMAN; SPRAY DRYING; SUSPENSION; ANIMAL; BIOSYNTHESIS; INHALATIONAL DRUG ADMINISTRATION; SCANNING ELECTRON MICROSCOPY;

ADMINISTRATION, INHALATION; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; GUINEA PIGS; HEPATITIS B ANTIBODIES; HEPATITIS B ANTIGENS; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES;

EID: 77955967773     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-010-9192-2     Document Type: Article

References (39)

1. World Health Organization. Hepatitis B Factsheet No. 204 (revised August 2008). Geneva: World Health Organization; 2008.
2. RJ Fontana 2003 Management of patients with decompensated HBV cirrhosis Semin Liver Dis 23 1 89 100 10.1055/s-2003-37591 1:CAS:528:DC%2BD3sXisFamtrY%3D 12616454
3. A Monto TL Wright 2001 The epidemiology and prevention of hepatocellular carcinoma Semin Oncol 28 5 441 9 10.1016/S0093-7754(01)90137-X 1:STN:280:DC%2BD3MngvVOhtw%3D%3D 11685737
4. H Chong K Brady D Metze E Calonje 2006 Persistent nodules at injection sites (aluminium granuloma)-clinicopathological study of 14 cases with a diverse range of histological reaction patterns Histopathology 48 2 182 8 10.1111/j.1365-2559.2005.02312.x 1:STN:280:DC%2BD28%2FitVWjsw%3D%3D 16405667
5. SA Moschos VW Bramwell S Somavarapu HO Alpar 2004 Adjuvant synergy: the effects of nasal coadministration of adjuvants Immunol Cell Biol 82 6 628 37 10.1111/j.0818-9641.2004.01280.x 1:CAS:528:DC%2BD2cXhtFakur%2FI 15550121
6. MJ McCluskie YM Wen Q Di HL Davis 1998 Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes Viral Immunol 11 4 245 52 10.1089/vim.1998.11.245 1:CAS:528:DyaK1MXitFKgtrw%3D 10189191
7. KS Jaganathan SP Vyas 2006 Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally Vaccine 24 19 4201 11 10.1016/j.vaccine.2006.01.011 1:CAS:528:DC%2BD28XksFejs7w%3D 16446012
8. Olszewska W, Openshaw PJM. Mucosal vaccination. In: Kaufmann SHE, editor. Novel vaccination strategies. Weinheim: Wiley-VCH GmbH & Co. KGaA; 2004. p. 343-64.
9. M Isaka Y Yasuda M Mizokami S Kozuka T Taniguchi K Matano, et al. 2001 Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant Vaccine 19 11-12 1460 6 10.1016/S0264-410X(00)00348-0 1:CAS:528:DC%2BD3MXktl2jsA%3D%3D 11163669
10. MJ McCluskie CL Brazolot Millan RA Gramzinski HL Robinson JC Santoro JT Fuller, et al. 1999 Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates Mol Med 5 5 287 300 1:CAS:528:DyaK1MXltVWht78%3D 10390545
11. A Joseph I Louria-Hayon A Plis-Finarov E Zeira Z Zakay-Rones E Raz, et al. 2002 Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines Vaccine 20 27-28 3342 54 10.1016/S0264-410X(02)00295-5 1:CAS:528:DC%2BD38Xms1OlsL4%3D 12213404
12. K Eriksson J Holmgren 2002 Recent advances in mucosal vaccines and adjuvants Curr Opin Immunol 14 5 666 72 10.1016/S0952-7915(02)00384-9 1:CAS:528:DC%2BD38XmtlGis7c%3D 12183170
13. A Kane J Lloyd M Zaffran L Simonsen M Kane 1999 Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates Bull World Health Organ 77 10 801 7 1:STN:280:DC%2BD3c%2FmtVKisA%3D%3D 10593027
14. World Health Organization. Safety of injections: global facts and figures. Geneva: World Health Organization; 2004.
15. CL Lai V Ratziu MF Yuen T Poynard 2003 Viral hepatitis B Lancet 362 9401 2089 94 10.1016/S0140-6736(03)15108-2 1:CAS:528:DC%2BD3sXpvFylsb4%3D 14697813
16. JN Zuckerman AJ Zuckerman 2000 Current topics in hepatitis B J Infect 41 2 130 6 10.1053/jinf.2000.0720 1:STN:280:DC%2BD3M%2Fot1ymsw%3D%3D 11023756
17. H Varmus R Klausner E Zerhouni T Acharya AS Daar PA Singer 2003 Public health. Grand challenges in global health Science 302 5644 398 9 10.1126/science.1091769 1:CAS:528:DC%2BD3sXotlSgu7c%3D 14563993
18. BN Lambrecht JB Prins HC Hoogsteden 2001 Lung dendritic cells and host immunity to infection Eur Respir J 18 4 692 704 1:CAS:528:DC%2BD3MXpt1Kisr8%3D 11716176
19. C von Garnier L Filgueira M Wikstrom M Smith JA Thomas DH Strickland, et al. 2005 Anatomical location determines the distribution and function of dendritic cells and other APCs in the respiratory tract J Immunol 175 3 1609 18
20. PG Holt 2005 Pulmonary dendritic cells in local immunity to inert and pathogenic antigens in the respiratory tract Proc Am Thorac Soc 2 2 116 20 10.1513/pats.200502-017AW 1:CAS:528:DC%2BD28XhsFGit7w%3D 16113478
21. L Garcia-Contreras YL Wong P Muttil D Padilla J Sadoff J Derousse, et al. 2008 Immunization by a bacterial aerosol Proc Natl Acad Sci U S A 105 12 4656 60 10.1073/pnas.0800043105 1:CAS:528:DC%2BD1cXkt12qs7w%3D 18344320
22. M Amidi HC Pellikaan H Hirschberg AH de Boer DJ Crommelin WE Hennink, et al. 2007 Diphtheria toxoid-containing microparticulate powder formulations for pulmonary vaccination: preparation, characterization and evaluation in guinea pigs Vaccine 25 37-38 6818 29 10.1016/j.vaccine.2007.05.064 1:CAS:528: DC%2BD2sXpvF2qs7o%3D 17692440
23. FT Cutts CJ Clements JV Bennett 1997 Alternative routes of measles immunization: a review Biologicals 25 3 323 38 10.1006/biol.1997.0103 1:STN:280:DyaK2svmslartw%3D%3D 9325001
24. JC Sung BL Pulliam DA Edwards 2007 Nanoparticles for drug delivery to the lungs Trends Biotechnol 25 12 563 70 10.1016/j.tibtech.2007.09.005 1:CAS:528:DC%2BD2sXhtlCru7nK 17997181
25. B Pulliam JC Sung DA Edwards 2007 Design of nanoparticle-based dry powder pulmonary vaccines Expert Opin Drug Deliv 4 6 651 63 10.1517/17425247.4.6.651 1:CAS:528:DC%2BD2sXht1elsr3L 17970667
26. D Lu AJ Hickey 2007 Pulmonary vaccine delivery Expert Rev Vaccin 6 2 213 26 10.1586/14760584.6.2.213 1:CAS:528:DC%2BD2sXjvVKjsLc%3D
27. M Dandri TK Volz M Lutgehetmann J Petersen 2005 Animal models for the study of HBV replication and its variants J Clin Virol 34 Suppl 1 S54 62 10.1016/S1386-6532(05)80011-3 1:CAS:528:DC%2BD28XhtlGnu7g%3D 16461225
28. RK Gupta GR Siber 1995 Adjuvants for human vaccines-current status, problems and future prospects Vaccine 13 14 1263 76 10.1016/0264-410X(95)00011-O 1:CAS:528:DyaK28XisFGg 8585280
29. Z Valinger A Trescec J Tomasic 1990 Comparison of immunogenicity of recombinant and plasma-derived hepatitis B antigen in guinea pigs Vaccine 8 6 585 9 10.1016/0264-410X(90)90014-D 1:CAS:528:DyaK3MXmt12rt7s%3D 2087880
30. T Kamiyama H Sato T Takahara S Kageyama K Shiraki 2000 Novel immunogenicity of Oka varicella vaccine vector expressing hepatitis B surface antigen J Infect Dis 181 3 1158 61 10.1086/315336 1:CAS:528:DC%2BD3cXivVOnsrk%3D 10720546
31. JS Moynihan FI D'Mello CR Howard 2000 48-mer synthetic peptide analogue of the hepatitis B virus "a" determinant induces an anti-HBs antibody response after a single injection J Med Virol 62 2 159 66 10.1002/1096- 9071(200010)62:2<159::AID-JMV6>3.0.CO;2-X 1:CAS:528:DC%2BD3cXmvFKnsLY%3D 11002244
32. S Phumiamorn H Sato T Kamiyama M Kurokawa K Shiraki 2003 Induction of humoral and cell-mediated immunity to hepatitis B surface antigen by a novel adjuvant activity of Oka varicella vaccine J Gen Virol 84 Pt 2 287 91 10.1099/vir.0.18692-0 1:CAS:528:DC%2BD3sXhtVWks7o%3D 12560559
33. Broderick A, Jonas MM. Hepatitis B and D viruses. In: Feigin RD, Demmler GJ, Cherry JD, Kaplan SL, editors. Textbook of pediatric infectious diseases. 5th ed. Foster City: W. B. Saunders; 2003. p. 1863-83.
34. HY Li H Neill R Innocent P Seville I Williamson JC Birchall 2003 Enhanced dispersibility and deposition of spray-dried powders for pulmonary gene therapy J Drug Target 11 7 425 32 10.1080/10611860410001659786 1:CAS:528: DC%2BD2cXjtFOjs7s%3D 15203931
35. AR Najafabadi K Gilani M Barghi M Rafiee-Tehrani 2004 The effect of vehicle on physical properties and aerosolisation behaviour of disodium cromoglycate microparticles spray dried alone or with L-leucine Int J Pharm 285 1-2 97 108 10.1016/j.ijpharm.2004.07.027 1:CAS:528:DC%2BD2cXosFSrsb0%3D 15488683
36. HL Davis R Weeratna TJ Waldschmidt L Tygrett J Schorr AM Krieg 1998 CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen J Immunol 160 2 870 6 1:CAS:528: DyaK1cXls1Chug%3D%3D 9551923
37. W Jilg M Schmidt F Deinhardt 1988 Persistence of specific antibodies after hepatitis B vaccination J Hepatol 6 2 201 7 10.1016/S0168-8278(88)80032-1 1:STN:280:DyaL1czhsFKrtA%3D%3D 2970501
38. Mahoney FJ, Kane M. Hepatitis B vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines. 3rd ed. Philadelphia: W.B. Saunders Company; 1999. p. 158-82.
39. Singh M, O' Hagan DT. Microparticles as vaccine adjuvants and delivery systems. In: Kaufmann SHE, editor. Novel vaccination strategies. Weinheim: Wiley-VCH; 2004. p. 148-72.